Literature DB >> 23115103

Myoclonus and dystonia in cerebrotendinous xanthomatosis.

Julien Lagarde1, Emmanuel Roze, Emmanuelle Apartis, Deepa Pothalil, Frédéric Sedel, Philippe Couvert, Marie Vidailhet, Bertrand Degos.   

Abstract

BACKGROUND: Cerebrotendinous xanthomatosis (CTX) is an inherited neurometabolic disorder. The main neurological manifestations of the disease are pyramidal syndrome, ataxia, peripheral neuropathy, cognitive impairment, epilepsy, and psychiatric disturbances. Myoclonic dystonia has been reported on in the setting of various neurometabolic diseases. Anecdotal reports describe movement disorders associated with CTX, but no dystonia with myoclonic events.
METHODS: We collected clinical, biochemical, electrophysiological, neuroradiological, and genetic data of 6 patients with myoclonus and mild dystonia associated with CTX. From a systematic literature review, we analyzed 31 patients with movement disorders secondary to CTX.
RESULTS: Our 6 patients presented distal myoclonus with mild dystonia of the upper limbs. Myoclonus was of subcortical origin, based on neurophysiological recordings, and differed from oromandibular myoclonus previously described in CTX patients.
CONCLUSIONS: These results expand the phenotype of CTX and suggest that myoclonus and/or dystonia are underdiagnosed. In keeping with our findings, tremors previously observed in CTX patients might actually correspond to myoclonic events. We hypothesize that a dysfunction of the dentate nuclei-basal ganglia pathway may be involved.
Copyright © 2012 Movement Disorder Society.

Entities:  

Mesh:

Year:  2012        PMID: 23115103     DOI: 10.1002/mds.25206

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  10 in total

Review 1.  Ataxia.

Authors:  Umar Akbar; Tetsuo Ashizawa
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

2.  Dystonia in Patients With Spinocerebellar Ataxia Type 2.

Authors:  Vladana Markovic; Natasa T Dragasevic-Miskovic; Iva Stankovic; Igor Petrovic; Marina Svetel; Vladimir S Kostić
Journal:  Mov Disord Clin Pract       Date:  2015-12-14

3.  A novel frameshift mutation in the sterol 27-hydroxylase gene in an Egyptian family with cerebrotendinous xanthomatosis without cataract.

Authors:  Mohamed S Abdel-Hamid; Mahmoud Y Issa; Ghada A Otaify; Maha S Zaki
Journal:  Metab Brain Dis       Date:  2017-02-22       Impact factor: 3.584

Review 4.  Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management.

Authors:  Shuke Nie; Guiqin Chen; Xuebing Cao; Yunjian Zhang
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

5.  Natural history of cerebrotendinous xanthomatosis: a paediatric disease diagnosed in adulthood.

Authors:  Bertrand Degos; Yann Nadjar; Maria del Mar Amador; Foudil Lamari; Frédéric Sedel; Emmanuel Roze; Philippe Couvert; Fanny Mochel
Journal:  Orphanet J Rare Dis       Date:  2016-04-16       Impact factor: 4.123

6.  A Treatable Rare Cause of Progressive Ataxia and Palatal Tremor.

Authors:  Malco Rossi; Martin Cesarini; Emilia M Gatto; Angel Cammarota; Marcelo Merello
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2018-05-17

7.  Subcortical Myoclonus and Associated Dystonia in 22q11.2 Deletion Syndrome.

Authors:  Vincent Van Iseghem; Eavan McGovern; Emmanuelle Apartis; Boris Keren; Marie Vidailhet; Emmanuel Roze; Bertrand Degos
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2020-01-24

8.  Progressive Myoclonic Epilepsy'-like presentation of Cerebrotendinous Xanthomatosis in an Indian Family with A Novel C.646+1G>A Splice Site Mutation.

Authors:  Karan M Desai; Piyush Kumar; Parthvi S Ravat; Sangeeta H Ravat; Neeraj Jain; Shruti Agrawal; Rahil Ansari
Journal:  Epilepsy Behav Rep       Date:  2020-11-16

Review 9.  Treatable Hyperkinetic Movement Disorders Not to Be Missed.

Authors:  Aurélie Méneret; Béatrice Garcin; Solène Frismand; Annie Lannuzel; Louise-Laure Mariani; Emmanuel Roze
Journal:  Front Neurol       Date:  2021-12-01       Impact factor: 4.003

10.  Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments.

Authors:  Shingo Koyama; Yoshiki Sekijima; Masatsune Ogura; Mika Hori; Kota Matsuki; Takashi Miida; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-05-08       Impact factor: 4.928

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.